Brugada syndrome {#sec1-1}
================

Brugada syndrome (BrS) is a genetic heart disorder with an ion channel dysfunction associated with progressive age-related conduction abnormalities. It is more prevalent among males. It is estimated to be responsible for up to 20% of all sudden deaths in individuals with apparently normal hearts ([@ref1]). BrS has a prevalence of 5:10000 ([@ref2]).

Diagnosis is based on clinical and family history and electrocardiographic examination. Penetrance and expressivity are highly variable ([@ref3]). Symptoms are often absent in the first year of life, and in adults usually manifest as syncope or sudden death at rest, during sleep or with fever. Sometimes they manifest on administration of drugs such as sodium channel blockers.

BrS is usually inherited in an autosomal dominant manner, however digenic or autosomal recessive inheritance in patients with mutations in *SCN5A* and *TRPM4* has been reported ([@ref4],[@ref5]). The genes associated with BrS encode subunits of cardiac sodium, potassium and calcium channels and proteins involved in the trafficking or regulation of these channels ([Table 1](#T1){ref-type="table"}). Only \~35% of BrS patients have been found to have a well-defined genetic cause, one third of whom carry a pathogenic mutation in *SCN5A* ([@ref6]). All other genes together are responsible for about 5% of BrS cases. Pathogenic variants are usually point mutations or small insertions/deletions, however partial *SCN5A* gene deletion has been reported ([@ref7]). Most of the reported patients inherit the mutation from one of their parents, while *de novo* variants account for \<1% ([@ref8]).

###### 

Genes associated with various forms of Brugada syndrome (BrS).

  Gene         OMIM gene   Disease   OMIM disease   Inheritance   Function
  ------------ ----------- --------- -------------- ------------- --------------------------------------------------------------------------------------------------------------------
  *SCN5A*      600163      BrS1      601144         AD, DR        Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *GPD1L*      611778      BrS2      611777         AD            Decreases cardiac Na^+^ current
  *CACNA1C*    114205      BrS3      611875         AD            Pore-forming, alpha-1C subunit of voltage-gated Ca^2^+ channel
  *CACNB2*     600003      BrS4      611876         AD            Increases cardiac peak Ca2+ current, regulates voltage- dependent activation, controls alpha-1 subunit recruitment
  *SCN1B*      600235      BrS5      612838         AD            Regulates assembly, expression and function of Na^+^ channel complex
  *KCNE3*      604433      BrS6      613119         AD            Modulates gating kinetics, stabilizes channel complex
  *SCN3B*      608214      BrS7      613120         AD            Modulates channel gating kinetics
  *HCN4*       605206      BrS8      613123         AD            Contributes to native pacemaker currents in the heart that regulate heartbeat rhythm
  *KCND3*      605411      BrS9      616399         AD            Pore-forming subunit of voltage-gated rapidly- inactivating A-type K+ channels
  *ABCC9*      601439      BrS       /              AD            Subunit of ATP-sensitive K^+^ channels
  *SCN10A*     604427      BrS       /              AD            Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *SLMAP*      602701      BrS       /              AD            Excitation-contraction coupling
  *SCN2B*      601327      BrS       /              AD            Assembly, expression and modulation of Na^+^ channel complex
  *CACNA2D1*   114204      BrS       /              AD            Regulates Ca^2+^ current density and activation/inactivation of Ca^2+^ channel
  *KCNJ8*      600935      BrS       /              AD            Inward-rectifier K^+^ channel
  *PKP2*       602861      BrS       /              AD            Maintains transcription of genes that control intracellular calcium cycling
  *TRPM4*      606936      BrS       /              AR, DR        Ca^2+^ -activated non selective cation channel that depolarizes membranes

AD=autosomal dominant; AR=autosomal recessive; DR= digenic recessive.

We use a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and multiplex ligation-dependent probe amplification (MLPA) assay to detect duplications and deletions in *SCN5A*. Worldwide, 81 accredited medical genetic laboratories in the EU and 57 in the US, listed in Orphanet ([@ref9]) and GTR ([@ref10]) databases, respectively, offer genetic tests for Brugada syndrome. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]) and GeneReviews ([@ref12]).

Catecholaminergic polymorphic ventricular tachycardia {#sec1-2}
=====================================================

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited heart disorder characterized by electrical instability in a structurally normal heart during acute activation of the adrenergic nervous system, as in physical activity or emotional stress. Release of catecholamines causes a calcium-ion channel dysfunction in myocytes, leading to ventricular arrhythmia. Episodes of ventricular tachycardia can cause dizziness and syncope. Spontaneous recovery from the arrhythmia is possible, but unless recognized and treated, ventricular tachycardia may cause cardiac arrest and sudden death. These symptoms typically begin in childhood. The exact prevalence of CPVT in the population is not known, but is estimated at about 1:10000 ([@ref13]).

Clinical diagnosis may be difficult because echocardiograms and electrocardiograms are normal in resting state. Testing must therefore be performed under stress. Differential diagnosis should consider long-QT syndrome, arrhythmogenic right ventricular cardiomyopathy, short coupled ventricular tachycardia and Andersen-Tawil syndrome.

Preventive drugs (beta-blockers and flecainide) and other treatments (implantable cardioverter defibrillator and left cardiac sympathetic denervation) are available for susceptible individuals.

The disorder may have autosomal dominant or recessive inheritance and the associated genes are involved in calcium homeostasis in myocytes ([Table 2](#T2){ref-type="table"}). Most pathogenic variants are point mutations or small insertions/deletions. However, large deletions/duplications and complex genomic rearrangements have been reported in RYR2 ([@ref1]). Pathogenic variants in these genes account for 55-65% of CPVT cases with a penetrance of 83% for *RYR2*-mutations carrier([@ref13]).

###### 

Genes associated with various forms of catecholaminergic polymorphic ventricular tachycardia

  Gene      OMIM gene   Disease                              OMIM disease   Inheritance   Function
  --------- ----------- ------------------------------------ -------------- ------------- ----------------------------------------------------------------------
  *RYR2*    180902      CPVT1                                604772         AD            Ca^2+^ channel triggers cardiac muscle contraction
  *CASQ2*   114251      CPVT2                                611938         AR            Regulates release of luminal Ca^2+^ via RYR2
  *TECRL*   617242      CPVT3                                614021         AR            Ca^2+^ transport into myocytes
  *CALM1*   114180      CPVT4                                614916         AD            Regulates release of Ca^2+^ via RYR2
  *TRDN*    603283      CPVT5 with/without muscle weakness   615441         AR            Regulates release of luminal Ca^2+^ release via RYR1 and RYR2
  *KCNJ2*   600681      CPVT                                 /              AD            Establishes action potential and excitability of neurons and muscles

AD=Autosomal dominant; AR=Autosomal recessive

We use a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the genes in [Table 2](#T2){ref-type="table"}. Worldwide, 25 accredited medical genetic laboratories in the EU and 19 in the US, listed in Orphanet ([@ref9]) and GTR ([@ref10]) databases, respectively, offer genetic tests for catecholaminergic polymorphic ventricular tachycardia. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]), GeneReviews ([@ref13]) and EuroGentest ([@ref14]).

Long QT syndrome {#sec1-3}
================

Long QT syndrome (LQT) is a genetic heart disease characterized by prolongation of the QT interval in the absence of other conditions known to lengthen it (such as QT-prolonging drugs). This may lead to arrhythmia that can cause palpitations, syncope or sudden death. Typically LQTS manifests in patients under 40 years of age, sometimes in early infancy. The mean age of onset of symptoms is 12 years and earlier onset is usually associated with severer forms ([@ref15],[@ref16]).

LQT follows two distinct patterns of inheritance: autosomal dominant with an estimated prevalence of 1:2000-5000 ([@ref17],[@ref18],[@ref19]) and autosomal recessive (Jervell and Lange-Nielsen syndrome) with an estimated prevalence of 1:1000000-4000000 ([@ref20]).

Clinical diagnosis is based on clinical findings, ECG, medical and family history. The genetic test is useful for diagnosis confirmation, differential diagnosis, recurrence risk evaluation and prenatal diagnosis. Differential diagnosis should consider QT-prolonging drugs, hypokalemia, structural heart disease, sudden infant death syndrome, vasovagal syncope, seizures, familial ventricular fibrillation, hypertrophic cardiomyopathy, dilative cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia ([@ref21]).

Syndromic LQT may have autosomal dominant (Timothy syndrome, Andersen-Twail syndrome and Ankyrin B syndrome) ([@ref22],[@ref23],[@ref24]) or autosomal recessive inheritance (Jervell and Lange-Nielsen syndromes) ([@ref20]). Up to 80% of cases of LQT are due to pathogenic variants in the *KCNQ1*, *KCNH2* and *SCN5A* genes. Other associated genes account for less than 5% of all cases ([@ref21]) ([Table 3](#T3){ref-type="table"}).

###### 

Genes associated with various forms of long QT syndrome

  Gene        OMIM gene   Disease   OMIM disease   Inheritance   Function
  ----------- ----------- --------- -------------- ------------- ---------------------------------------------------------------------------------------------------------------------
  *KCNQ1*     607542      LQT1      192500         AD            Repolarizes cardiac action potential
  JLNS1       220400      AR                                     
  *KCNH2*     152427      LQT2      613688         AD            Pore-forming subunit of voltage-gated inwardly rectifying K^+^ channel
  *SCN5A*     600163      LQT3      603830         AD            Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *ANK2*      106410      LQT4      600919         AD            Coordinates assembly of Na/Ca exchanger, Na/K ATPase and InsP3 receptor in sarcoplasmic reticulum of cardiomyocytes
  *KCNE1*     176261      LQT5      613695         AD            Modulates gating kinetics and enhances stability of voltage-gated K+ channel complex
  JLNS2       612347      AR                                     
  *KCNE2*     603796      LQT6      613693         AD            Modulates gating kinetics and enhances stability of voltage-gated K+ channel complex
  *KCNJ2*     600681      LQT7      170390         AD            Establishes neuron and muscle action potentials and excitability
  *CACNA1C*   114205      LQT8      601005         AD            Pore-forming, alpha-1C subunit of voltage- gated Ca^2+^ channel
  *CAV3*      601253      LQT9      611818         AD            Regulates voltage-gated K^+^ channels
  *SCN4B*     608256      LQT10     611819         AD            Interacts with voltage-gated alpha subunits to change Na^+^ channel kinetics
  *AKAP9*     604001      LQT11     611820         AD            Effector in regulating K^+^ channel
  *SNTA1*     601017      LQT12     612955         AD            Interacts with pore-forming alpha subunit of cardiac Na^+^ channel
  *KCNJ5*     600734      LQT13     613485         AD            Allows K^+^ flow into cells
  *CALM1*     114180      LQT14     616247         AD            Mediates ion channel control
  *CALM2*     114182      LQT15     616249         AD            Mediates ion channel control
  *CALM3*     114183      LQT       /              AD            Mediates ion channel control

AD=autosomal dominant; AR=autosomal recessive; JLNS=Jervell and Lange-Nielsen syndrome

Pathogenic variants may be sequence variations (missense, nonsense, splicing, small insertions and deletions, small indels). Large deletions/duplications have been reported in *KCNH2*, *KCNQ1* and *KCNJ2* ([@ref21],[@ref23]). We use a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA assay to detect duplications and deletions in *KCNH2*, *KCNQ1* and *KCNJ2*.

Worldwide, 52 accredited medical genetic laboratories in the EU and 4 in the US, listed in the Orphanet ([@ref9]) and GTR ([@ref10]) databases, respectively, offer genetic tests for long QT syndrome. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]), GeneReviews ([@ref20],[@ref21],[@ref22],[@ref23],[@ref24]) and EuroGentest ([@ref14]).

Short QT syndrome {#sec1-4}
=================

Short QT syndrome (SQT) is a rare genetic heart disease characterized by an abnormally short QT interval and increased risk of arrhythmia and sudden death. Clinical presentation is heterogeneous. Some patients may be totally asymptomatic and others may have episodes of syncope or fall victim to sudden cardiac death. SQT may occur at any time of life from early infancy to old age. The estimated prevalence is 1-5:1000 ([@ref26],[@ref27],[@ref28],[@ref29]).

According to the 2013 consensus statement of major world heart associations, the recommended criteria for diagnosis of SQT are QTc \<330 msec or \<360 msec with one or more of the following: a pathogenic mutation, family history of SQT, family history of sudden death under 40 years of age, or survival of a ventricular tachycardia/ventricular fibrillation event without underlying heart disease ([@ref30]).

Differential diagnosis should consider the secondary causes of SQT interval (hyperkalaemia, hypercalcemia, hyperthermia, acidosis, effects of catecholamines or drugs such as digitalis) ([@ref31]) and other arrhythmic disorders, such as Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, cardiac arrest and sick sinus syndrome ([Table 4](#T4){ref-type="table"}).

###### 

Genes associated with various forms of short QT syndrome

  Gene      OMIM gene   Disease   OMIM disease   Inheritance   Function
  --------- ----------- --------- -------------- ------------- ------------------------------------------------------------------------
  *KCNH2*   152427      SQT1      609620         AD            Pore-forming subunit of voltage-gated inwardly rectifying K^+^ channel
  *KCNQ1*   607542      SQT2      609621         AD            Repolarizes cardiac action potential
  *KCNJ2*   600681      SQT3      609622         AD            Establishes action potential and excitability of neurons and muscles

AD=autosomal dominant; AR=autosomal recessive

Pathogenic variants may be sequence variations (missense, nonsense, splicing, small indels). Large deletions/duplications associated with SQT have not yet been reported in the above genes.

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes. 26 accredited medical genetic laboratories in the EU and 32 in the US, listed in the Orphanet and GTR databases, respectively, offer genetic tests for short QT syndrome. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]).

Wolff-Parkinson-White syndrome {#sec1-5}
==============================

Wolff-Parkinson-White syndrome (WPWS), also known as "pre-excitation syndrome", is a genetic heart disorder characterized by arrhythmia due to an abnormal electrical pathway in the heart, a so-called accessory pathway that allows electrical signals to bypass the atrioventricular node and move faster than normal from the atria to the ventricles. It may also transmit reverse electrical impulses, resulting in arrhythmias ([@ref32]).

Wolff-Parkinson-White syndrome may present clinically with palpitations, dyspnea, dizziness or even syncope. In rare cases it can lead to cardiac arrest and sudden death ([@ref33]). Although age of onset ranges from 11 to 50 years, complications can occur at any age. Some patients, however, are totally asymptomatic or never experience any complication associated with this condition.

In most patients, WPWS is sporadic, though in a minority of cases it can be familial ([@ref34]) or complicated underlying diseases, such as Ebstein's anomaly ([@ref35]), mitochondrial disease ([@ref36]), hypertrophic cardiomyopathy ([@ref37]) or a lethal congenital form of glycogen storage disease ([@ref38]). The estimated prevalence of WPWS is 1.5-3.1:1000 in western countries ([@ref33]).

Clinical diagnosis is based on clinical history, physical examination, resting 12-lead ECG and Holter monitoring. Genetic testing is useful for confirming diagnosis and for differential diagnosis, recurrence risk calculation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider other primary channelopathies and secondary causes of arrhythmia, such as electrolyte abnormalities, hyperthyroidism and/or side effects of substances such as digoxin and alcohol ([@ref39]).

Familial WPWS only accounts for a small percentage of cases, most of which occur in persons with no apparent family history of the condition. The familial form has autosomal dominant inheritance and is associated with variations in the *PRKAG2* gene (OMIM gene 602743; OMIM disease 194200). Pathogenic variants may be missense, nonsense, splicing or small insertions/deletions.

No genetic tests are listed in the Orphanet database but 10 accredited medical genetic laboratories in the US, listed in the GTR database, offer genetic testing for WPWS. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]). MAGI uses an NGS approach to detect nucleotide variations in coding exons and flanking introns of the above gene.

Familial atrial fibrillation {#sec1-6}
============================

Familial atrial fibrillation (FAF) is a heterogeneous genetic heart disorder characterized by chaotic electrical activity in the atria and an irregular ventricular response. This is also known as "irregularly irregular rhythm". If untreated, it can lead to reduction in cardiac output and atrial thrombus formation, which may be responsible for episodes of stroke or sudden death. Atrial fibrillation may manifest clinically with palpitations, dyspnea, chest pain, dizziness or even syncope ([@ref40]). The risk of developing atrial fibrillation increases with age and complications can occur at any age. However, some patients are totally asymptomatic or never experience any complication associated with this condition. The estimated prevalence of FAF ranges from 0.4% to 1% in the general population ([@ref40]) and increases with age ([@ref41]).

Clinical diagnosis is based on clinical history, physical examination, ECG and Holter monitoring. Echocardiography is performed to evaluate left chamber dimensions and systolic/diastolic performance. Genetic testing is useful for confirming diagnosis, and for differential diagnosis, recurrence risk calculation and prenatal diagnosis in families with a known mutation. Differential diagnosis should consider: reversible causes of atrial fibrillation (AF), such as alcohol intake, surgery, myocardial infarction, myocarditis and pericarditis; metabolic disorders associated with AF, such as obesity and hyperthyroidism; other heart diseases associated with AF, such as valve disease, heart failure, hypertension, hypertrophic cardiomyopathy and dilated cardiomyopathy ([@ref40], [@ref42]).

Eligibility criteria for genetic testing ([@ref43]) are:

1.  ECG characteristics: absence of P waves; irregular R-R intervals;

2.  clinical presentation: AF as major clinical manifestation (phenotype) with early onset (before age 60 years);

3.  family history: at least one affected first or second-degree family member.

Familial atrial fibrillation is highly heterogeneous and can have autosomal dominant or recessive inheritance ([Table 5](#T5){ref-type="table"}).

###### 

Genes associated with various forms of atrial fibrillation, familial (ATFB)

  Gene       OMIM gene   Disease   OMIM disease   Inheritance   Function
  ---------- ----------- --------- -------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------
  *KCNQ1*    607542      ATFB3     607554         AD            Repolarizes cardiac action potential
  *KCNE2*    603796      ATFB4     611493         AD            Modulates gating kinetics and enhances stability of voltage-gated K^+^ channel complex
  *NPPA*     108780      ATFB6     612201         AD            Key role in regulation of natriuresis, diuresis, vasodilation
  *KCNA5*    176267      ATFB7     612240         AD            Mediates transmembrane potassium transport in excitable membranes
  *KCNJ2*    600681      ATFB9     613980         AD            Establishes action potential and excitability of neurons and muscles
  *SCN5A*    600163      ATFB10    614022         AD            Mediates voltage-dependent Na^+^ permeability of excitable membranes
  *GJA5*     121013      ATFB11    614049         AD            Allows passive diffusion of small molecules, including glucose, K^+^, Ca^2+^ and cAMP
  *ABCC9*    601439      ATFB12    614050         AD            Subunit of ATP-sensitive K^+^ channels
  *SCN1B*    600235      ATFB13    615377         AD            Regulates assembly, expression, function of Na^+^ channel complex
  *SCN2B*    601327      ATFB14    615378         AD            Assembly, expression, modulation Na^+^ channel complex
  *SCN3B*    608214      ATFB16    613120         AD            Modulates channel-gating kinetics
  *SCN4B*    608256      ATFB17    611819         AD            Interacts with voltage-gated alpha subunits to change Na^+^ channel kinetics
  *MYL4*     160770      ATFB18    617280         AD            Encodes a myosin alkali light chain expressed in embryonic muscle and adult atria
  *NUP155*   606694      ATFB15    615770         AR            Plays a role in fusion of nuclear envelope vesicles and may also be involved in heart physiology
  *KCND3*    605411      ATFB      /              AD            Pore-forming subunit of voltage-gated rapidly-inactivating A-type K^+^ channels
  *KCNE1*    176261      ATFB      /              AD            Modulates gating kinetics and enhances stability of voltage-gated K^+^ channel complex
  *KCNH2*    152427      ATFB      /              AD            Pore-forming subunit of voltage-gated inwardly rectifying K^+^ channels
  *LMNA*     150330      ATFB      /              AD            Component of nuclear lamina and required for cardiac homeostasis
  *NKX2-5*   600584      ATFB      /              AD            Transcription factor involved in heart formation and development
  *PRKAG2*   602743      ATFB      /              AD            Energy-sensing enzyme that monitors cell energy status and functions; inhibits de novo biosynthesis of fatty acids and cholesterol
  *RYR2*     180902      ATFB      /              AD            Ca^2+^ channel that triggers cardiac muscle contraction
  *GATA4*    600576      ATFB      /              AD            Regulates genes involved in myocardial differentiation and function
  *GATA5*    611496      ATFB      /              AD            Required for cardiovascular development
  *GATA6*    601656      ATFB      /              AD            Required for cardiovascular development
  *PITX2*    601542      ATFB      /              AD            May play a role in proper localization of asymmetric organs such as heart
  *TBX5*     601620      ATFB      /              AD            Regulates transcription of several genes involved in heart development
  *ZFHX3*    104155      ATFB      /              AD            Regulates myogenic differentiation
  *SHOX2*    602504      ATFB      /              AD            Transcriptional regulator involved in pattern formation in vertebrates
  *PRRX1*    167420      ATFB      /              AD            Role in establishment of diverse mesodermal muscle types
  *KCNN3*    602983      ATFB      /              AD            Forms a voltage-independent K^+^ channel activated by intracellular Ca^2+^

AD=autosomal dominant; AR=autosomal recessive

Pathogenic variants may be missense, nonsense, splicing or small small indels. Large deletions/duplications have also been reported in *KCNQ1, KCNA5, KCNJ2, SCN5A, GATA4, PTX2, TBX5* and *GJA5*. MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes and MLPA assay to detect duplications and deletions in *KCNQ1, KCNA5, KCNJ2, SCN5A, GATA4, PTX2, TBX5* and *GJA5*.

19 accredited medical genetic laboratories in the EU and 23 in the US, listed in the Orphanet and GTR databases, respectively, offer genetic tests for familial atrial fibrillation. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref11]).

Conclusions {#sec1-7}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with genetic cardiac disorders. When a suspect of cardiac conduction defect is present we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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